Copyright
©The Author(s) 2024.
World J Gastroenterol. Jan 28, 2024; 30(4): 318-331
Published online Jan 28, 2024. doi: 10.3748/wjg.v30.i4.318
Published online Jan 28, 2024. doi: 10.3748/wjg.v30.i4.318
Intervention | OR | Intervention | HR |
HAIC | 0.9520107 | HAIC + Sorafenib | 0.03757857 |
HAIC + Sorafenib | 0.9420071 | HAIC | 0.09333929 |
SIRT | 0.8131607 | TACE + Lenvatinib | 0.098075 |
TACE + Lenvatinib | 0.8014429 | Sintilimab + Bevacizumabbiosimila | 0.24973929 |
Sintilimab + Bevacizumabbiosimila | 0.6559643 | Camrelizumab + Rivoceranib | 0.30909286 |
Lenvatinib + Pembrolizumab | 0.5922857 | Atezolizumab + Bevacizumab | 0.35838929 |
Camrelizumab + Rivoceranib | 0.5853643 | Lenvatinib + Pembrolizumab | 0.51200714 |
Durvalumab + Tremelimumab | 0.523425 | Durvalumab + Tremelimumab | 0.52634286 |
Durvalumab | 0.3891893 | Donafenib | 0.62278571 |
Atezolizumab + Bevacizumab | 0.3369036 | Tislelizumab | 0.66164643 |
Lenvatinib | 0.3254286 | Nivolumab | 0.67260357 |
Tislelizumab | 0.2732107 | Durvalumab | 0.68975714 |
Nivolumab | 0.1859964 | Lenvatinib | 0.78121071 |
Donafenib | 0.1165357 | Sorafenib | 0.9135 |
Sorafenib | 0.007075 | SIRT | 0.97393214 |
Variable | Prior to PSM | Following PSM | ||||
Triple therapy (n = 324) | AIPB (n = 118) | P value | Triple therapy (n = 88) | AIPB (n = 88) | P value | |
Age | ||||||
Mean (SD) | 50.2 (11.2) | 55.4 (11.6) | < 0.001 | 54.2 (10.8) | 53.9 (11.2) | 0.859 |
Median [Min, Max] | 51.0 [23.0, 80.0] | 56.5 [23.0, 82.0] | 55.0 [26.0, 78.0] | 55.0 [23.0, 74.0] | ||
Sex | ||||||
Female | 36 (11.1) | 8 (6.8) | 0.244 | 11 (12.5) | 6 (6.8) | 0.307 |
Male | 288 (88.9) | 110 (93.2) | 77 (87.5) | 82 (93.2) | ||
ECOG PS | ||||||
0 | 318 (98.1) | 106 (89.8) | < 0.001 | 85 (96.6) | 85 (96.6) | 1 |
1 | 6 (1.9) | 11 (9.3) | 3 (3.4) | 3 (3.4) | ||
2 | 0 (0) | 1 (0.8) | 0 (0) | 0 (0) | ||
Hepatitis virus | ||||||
Negative | 27 (8.3) | 15 (12.7) | 0.228 | 11 (12.5) | 12 (13.6) | 1 |
Positive | 297 (91.7) | 103 (87.3) | 77 (87.5) | 76 (86.4) | ||
ALT | ||||||
mean (SD) | 62.4 (72.8) | 53.6 (34.9) | 0.0894 | 58.4 (60.5) | 53.2 (36.1) | 0.489 |
Median [Min, Max] | 44.6 [8.90, 930] | 45.4 [6.10, 196] | 41.1 [8.90, 448] | 44.6 [6.10, 196] | ||
AST | ||||||
mean (SD) | 92.5 (83.1) | 88.3 (78.5) | 0.627 | 82.0 (65.3) | 87.1 (84.9) | 0.657 |
Median [Min, Max] | 66.2 [13.5, 702] | 66.8 [11.1, 470] | 58.7 [13.5, 327] | 63.7 [11.1, 470] | ||
Child-Pugh class | ||||||
A | 296 (91.4) | 94 (79.7) | 0.00133 | 75 (85.2) | 77 (87.5) | 0.826 |
B | 28 (8.6) | 24 (20.3) | 13 (14.8) | 11 (12.5) | ||
AFP > 400 ng/mL | ||||||
No | 142 (43.8) | 60 (50.8) | 0.229 | 45 (51.1) | 42 (47.7) | 0.763 |
Yes | 182 (56.2) | 58 (49.2) | 43 (48.9) | 46 (52.3) | ||
Maximum diameter of tumor/cm | ||||||
mean (SD) | 10.5 (4.25) | 9.38 (4.75) | 0.0291 | 9.86 (4.07) | 9.57 (4.83) | 0.668 |
Median [Min, Max] | 10.3 [1.90, 23.5] | 9.25 [1.10, 21.0] | 10.0 [2.10, 19.2] | 9.10 [1.10, 20.5] | ||
Tumor number | ||||||
Single | 122 (37.7) | 19 (16.1) | < 0.001 | 21 (23.9) | 19 (21.6) | 0.857 |
Multiple | 202 (62.3) | 99 (83.9) | 67 (76.1) | 69 (78.4) | ||
Vascular invasion | ||||||
No | 78 (24.1) | 42 (35.6) | 0.0221 | 25 (28.4) | 30 (34.1) | 0.515 |
Yes | 246 (75.9) | 76 (64.4) | 63 (71.6) | 58 (65.9) | ||
Extrahepatic metastasis | ||||||
No | 171 (52.8) | 45 (38.1) | 0.00888 | 34 (38.6) | 38 (43.2) | 0.646 |
Yes | 153 (47.2) | 73 (61.9) | 54 (61.4) | 50 (56.8) | ||
BCLC | ||||||
A | 0 (0) | 2 (1.7) | 0.0632 | 0 (0) | 2 (2.3) | 0.309 |
B | 30 (9.3) | 11 (9.3) | 7 (8.0) | 9 (10.2) | ||
C | 294 (90.7) | 105 (89.0) | 81 (92.0) | 77 (87.5) |
Before PSM | After PSM | |||||||
Triple therapy group (n = 324) | AIPB group (n = 118) | Triple therapy group (n = 88) | AIPB group (n = 88) | |||||
Grade 1-2 | Grade 3-4 | Grade 1-2 | Grade 3-4 | Grade 1-2 | Grade 3-4 | Grade 1-2 | Grade 3-4 | |
Fever | 67 (20.7) | 23 (7.1) | 4 (3.4) | 2 (1.7) | 20 (22.7) | 8 (9.1) | 4 (4.5) | 0 (0) |
Nausea | 100 (30.9) | 0 (0) | 6 (5.1) | 0 (0) | 24 (27.3) | 0 (0) | 5 (5.7) | 0 (0) |
Vomit | 32 (9.9) | 15 (4.6) | 7 (5.9) | 6 (5.1) | 7 (8.0) | 3 (3.4) | 6 (6.8) | 4 (4.5) |
Abdominal pain | 97 (29.9) | 162 (50.0) | 18 (15.3) | 18 (15.3) | 24 (27.3) | 44 (50.0) | 15 (17.0) | 13 (14.8) |
ALT increased | 79 (24.4) | 125 (38.6) | 32 (27.1) | 39 (33.1) | 27 (30.4) | 33 (37.5) | 22 (25.0) | 29 (33.0) |
AST increased | 130 (40.1) | 161 (49.7) | 36 (30.5) | 44 (37.3) | 40 (45.5) | 49 (55.7) | 26 (29.5) | 34 (38.6) |
Hyperbilirubinemia | 37 (11.4) | 7 (2.2) | 7 (5.9) | 11 (9.3) | 10 (11.4) | 0 (0) | 4 (4.5) | 8 (9.1) |
Anemia | 37 (11.4) | 8 (2.5) | 7 (5.9) | 4 (3.4) | 11 (12.5) | 1 (1.1) | 5 (5.7) | 3 (3.4) |
Neutropenia | 86 (26.5) | 20 (6.2) | 9 (7.6) | 12 (10.2) | 29 (33.0) | 5 (5.7) | 5 (5.7) | 9 (10.2) |
Thrombocytopenia | 103 (31.8) | 90 (27.8) | 27 (22.9) | 20 (16.9) | 24 (27.3) | 16 (18.2) | 20 (22.7) | 13 (14.8) |
Bleeding | 48 (14.8) | 3 (0.9) | 1 (0.8) | 1 (0.8) | 12 (13.6) | 1 (1.1) | 1 (1.1) | 1 (1.1) |
Diarrhea | 62 (19.1) | 60 (18.5) | 22 (18.6) | 3 (2.5) | 17 (19.3) | 5 (5.7) | 17 (19.3) | 3 (3.4) |
Hoarseness | 80 (24.7) | 0 (0) | 13 (11.0) | 0 (0) | 21 (23.9) | 0 (0) | 10 (11.4) | 0 (0) |
Rash | 92 (28.4) | 4 (1.2) | 28 (23.7) | 4 (3.4) | 24 (27.3) | 0 (0) | 20 (22.7) | 3 (3.4) |
HFS | 69 (21.3) | 9 (2.8) | 19 (16.1) | 18 (15.3) | 18 (20.5) | 1 (1.1) | 14 (15.9) | 11 (12.5) |
Hypertension | 76 (23.5) | 11 (3.4) | 31 (26.3) | 34 (28.8) | 22 (25.0) | 3 (3.4) | 23 (26.1) | 27 (30.7) |
RCCEP | 42 (13.0) | 14 (4.3) | 16 (13.6) | 6 (5.1) | 11 (12.5) | 5 (5.7) | 13 (14.8) | 6 (6.8) |
Hypothyroidism | 64 (19.8) | 8 (2.5) | 2 (1.7) | 0 (0) | 18 (20.5) | 2 (2.3) | 0 (0) | 0 (0) |
Fatigue | 32 (9.9) | 31 (9.6) | 4 (3.4) | 4 (3.4) | 6 (6.8) | 8 (9.1) | 3 (3.4) | 2 (2.3) |
Hepatitis | 10 (3.1) | 1 (0.3) | 0 (0) | 0 (0) | 5 (5.7) | 1 (1.1) | 0 (0) | 0 (0) |
Coma | 0 (0) | 2 (0.6) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
- Citation: Cao YZ, Zheng GL, Zhang TQ, Shao HY, Pan JY, Huang ZL, Zuo MX. Hepatic arterial infusion chemotherapy with anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis. World J Gastroenterol 2024; 30(4): 318-331
- URL: https://www.wjgnet.com/1007-9327/full/v30/i4/318.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i4.318